In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic ...

Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic ...

OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek’s ...

Severe asthma and nasal polyposis: the care of patients with rhinological and respiratory disorders, in light of recent ...

A stuffy nose can make it incredibly difficult to get a good night’s sleep. When congestion blocks your nasal passages, ...

A new study published in the European Archives of Oto-Rhino-Laryngology revealed that serum 25(OH)D deficiency is an ...

Not only adults, nasal polyps can also occur in children. Polyps are an inflammation of the nasal membranes and sinuses that ...

Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

Request To Download Free Sample of This Strategic Report @- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...

Read the Market Summary Here:- https://reportocean.com/industry-verticals/sample-request?report_id=bw8527 ...